Gray zones in acute stroke reperfusion: bridging, distal medium vessel occlusion, and extended-window thrombolysis
Серые зоны реперфузии при остром инсульте: мостовая терапия, окклюзия дистальных сосудов среднего калибра и тромболизис в расширенном временном окне
2026-07-16
SCID: 54.1/eed629h4
Discuss with AI
acute ischemic strokedistal medium vessel occlusionextended-window thrombolysisintravenous thrombolysismechanical thrombectomy
Figures from the paper
Abstract (AI)
Intravenous thrombolysis (IVT) has been the mainstay of acute ischemic stroke (AIS) treatment for over three decades. Recently, several studies have evaluated the safety and efficacy of IVT in certain complex clinical scenarios such as bridging IVT with mechanical thrombectomy (MT) versus direct MT, MT in distal medium vessel occlusions (DMVOs), and extended time window reperfusion. Many of these scenarios overlap with neurointerventional treatment strategies. This updated evidence has uncovered certain nuances in AIS treatment (transfer vs non-transfer patients, degree of disability, feasibility of MT) that warrant consideration in medical decision-making in addition to the conventional risks-versus-benefits discussion. Furthermore, as an increasing number of neurologists with diverse subspecialty interests are involved in AIS triage and treatment decision-making across various patient-care models (telestroke, spoke and hub systems, etc), variability in data interpretation may lead to inconsistencies in the administration of these time-sensitive therapies. In this vignette-based narrative review, we focus on evolving ‘gray zones’ of AIS reperfusion therapy that are particularly relevant to neurointerventional practice: (1) bridging IVT before MT, and (2) reperfusion strategies for DMVOs, with the role of IVT in the extended time window primarily discussed within the second vignette and, to a lesser extent, in the first. This paper is not meant to be a treatment guideline but rather a case-based exercise to provide a better understanding of the new data in this area.
Key Findings
1
Interpretation of evolving evidence varies across neurologists and care models, including telestroke and spoke–hub systems, potentially causing inconsistent use of time-sensitive reperfusion therapies.
2
Recent studies have refined intravenous thrombolysis decision-making in complex acute ischemic stroke scenarios, including bridging before thrombectomy, distal medium vessel occlusion, and extended-window reperfusion.
3
The article is a vignette-based narrative review intended to improve understanding of emerging evidence rather than provide formal treatment guidelines.
4
The review focuses on two major evidence gray zones: bridging intravenous thrombolysis before mechanical thrombectomy and reperfusion strategies for distal medium vessel occlusions.
5
Treatment choices increasingly depend on contextual factors such as transfer status, baseline disability, and mechanical thrombectomy feasibility, beyond conventional risk–benefit assessment.
Research Object
acute ischemic stroke reperfusion therapy, including bridging intravenous thrombolysis before mechanical thrombectomy and treatment of distal medium vessel occlusions
Research Subject
evolving evidence, treatment decision-making, and safety and efficacy considerations for reperfusion strategies in bridging IVT, DMVO, and extended time-window scenarios
Publication Details
Publication Date
2026-07-16
Journal
Publisher
ISSN
Cited by
0
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association2019
2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association2026
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy2024
Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection2024